I-HP518 iye yafunyaniswa yaze yaphuhliswa liqonga leprotein ekujoliswe kulo likaHinova lokufunyanwa kweziyobisi. Inamandla okoyisa ukunganyangeki kwechiza lomhlaza wedlala lesidlala ngenxa yotshintsho oluthile oluthile lwe-AR.
I-Chimeric degraders ziyi-bifunctional molecules ezincinci ezikhuthaza ukuthotywa kweeprotheyini ezijoliswe kuyo kunye namandla aphezulu kunye nokukhetha okuphezulu. Obu buchwephesha bunakho ukujolisa kwiithagethi ezingasetyenziswayo kunye nokoyisa umba wokuxhathisa kumachiza kumachiza emolekyuli amancinci esintu.
"Oku kubalulekileyo kwinkqubela phambili yemigudu yethu yokufumana iziyobisi kwisifundo seklinikhi," watsho uYuanwei Chen, Ph.D., uMongameli kunye ne-CEO ye-Hinova. "Siyonwabile kwaye sizinikele ekuziseni iindlela zonyango olutsha kwizigulana kwihlabathi liphela!"
Ngeqonga elichongiweyo lokuthotywa kweprotheyini yokufumanisa iziyobisi, i-Hinova inokuhlola umsebenzi wokuthotywa kweprotheyini ngokukhawuleza kwaye ifezekise uyilo olusebenzayo kunye nokuphucula i-chimeric degraders. Ngapha koko, i-Hinova inamava anzulu ekulawuleni ukwenziwa kweekhemikhali kwi-Chimeric degrader compounds.
INTO ONOKUYITHATHA KWELI NQAKU:
- Through the targeted protein degradation drug discovery platform, Hinova can screen protein degradation activity rapidly and accomplish efficient design and optimization of chimeric degraders.
- “This is a significant milestone in the progress of our efforts from drug discovery to the clinical study,”.
- This technology has the potential to target non-druggable targets and to overcome the drug resistance issue of traditional small molecule drugs.
